TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: myocardial free amino acids levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL gain >3 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CAL gain >=4 mm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of patients with gastrointestinal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: CPTPS incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life improvement in physical domain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Mean plasma AUC values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway leak pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quantity of chorionic villi obtained
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal pancreatic parenchymal enhancement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal tumor-to-parenchyma attenuation differences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor conspicuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean values of temperature
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative humidity of inspired gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: absolute humidity of inspired gases
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early IL-6 change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of peanut allergy at 60 months of age
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: left ventricular end-diastolic pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiac and stroke volume index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: GpHi drop
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ventilation duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: QOL improving rate
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 3-year relapse and remote metastasis rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Serum troponin T levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax for d- and l-amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUClast for d- and l-amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf for d- and l-amphetamine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decision aid use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Equilibrium scores in SOT-6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Equilibrium scores in SOT-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incremental area under the glucose curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin sensitivity (S(I))
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sexual relationship satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Plasma adiponectin level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or myocardial infarction rates
Endpoint domain: Mortality/survival
Primary endpoint: Average Surface Deviation (Absolute Average Error, AAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dice Similarity Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical biomarkers improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence of injury
Endpoint domain: Adverse events/effects
Primary endpoint: CA125 normalization rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CA125 decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal plasma concentrations (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total serum calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urinary calcium/creatinine clearance ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: HLA alloantibody production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Need for additional medication for sedation or analgesia
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Linking tissue biomarkers to epidemiologic information
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of ioflupane ((123)I) imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of ioflupane ((123)I) imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial glucose distribution volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Initial C-peptide levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Left without complete assessment cases
Endpoint domain: Adverse events/effects
Primary endpoint: surgically induced astigmatism
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg-press 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Smith-machine bench-press 1RM
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: normal gait speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intercourse satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Orgasmic domain of IIEF
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: subsequent pregnancy
Endpoint domain: Mortality/survival
Primary endpoint: subsequent sex at risk for pregnancy
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Intraoperative pulmonary mechanics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acid-base balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: satisfaction with services
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Myocardial Infarction (MI) and Cardiac Death
Endpoint domain: Mortality/survival
Primary endpoint: syncope recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Death or HF readmission through 24 weeks
Endpoint domain: Mortality/survival
Primary endpoint: cognitive impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: subjective sedation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: digit vigilance accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lack of progression of CAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Increase in bEAT/wEAT ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reduction of homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: self-rated tinnitus loudness scale results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: continued abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliability of the BROM II for lumbar mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: persistent improvements in patient-reported HIV symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at port sites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initial bleeding control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Freedom from locoregional failure at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Median survival from time of diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Median survival from time of first [90Y-DOTA]‐TOC treatment
Endpoint domain: Mortality/survival
Primary endpoint: postoperative bruising
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: systolic blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: diastolic blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: success rates
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: Retention during the study
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Lower rates of opioid use based on urine toxicology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieving 3 or more consecutive weeks of abstinence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Primary CV composite risk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Lung recruitment volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung static compliance (Cst)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak airway pressure (PIP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clearance of inflammatory infiltrates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of extra fruit intake
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exercise endurance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: magnitude of treatment zone decentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: optimal adherence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: average daily use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: disease knowledge improvement
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: end tidal CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: dyspnoea
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of symptomatic adverse events related to chemotherapy
Endpoint domain: Adverse events/effects
Primary endpoint: Numeric rating scale for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean temperatures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of IPH
Endpoint domain: Adverse events/effects
Primary endpoint: Thermal comfort scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall progression-free survival
Endpoint domain: Mortality/survival
Primary endpoint: joint flexion improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma folate area under the curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative bioavailability of mesalazine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative urine excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actuarial survival rate at 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Reoperation-free survival rate at 48 months
Endpoint domain: Mortality/survival
Primary endpoint: Splanchnic blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: NoL index sensitivity and specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean urinary β2m level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reduction in erosive area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: elbow ROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perceived overall workload
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Participation in eight-week postpartum follow up visit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Frequency of pelvic floor exercises performed
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion with HIV RNA < 400 copies/ml
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Rate of surgical site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Coverage of at least two home visitations by ASHA within the first week of birth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite coverage index of MNCH services
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oral-related quality of life (OHIP-14)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in carotid arteriosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Improvement in blood flow in carotid artery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Development of symptomatic GERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Development of RE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Improvement in Interstitial Cystitis Symptom Index mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in Interstitial Cystitis Problem Index mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in pain by visual analog scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to reach clinically significant anxiolytic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of sialorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Severity of sialorrhoea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of neutrophil gelatinase‐associated lipocalin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FE(NO) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to management strategy
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient preference for management strategy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: RBP4 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebrovascular pressure-reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sensitivity of echo-enhanced power Doppler sonography for diagnosing pancreatic carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Specificity of echo-enhanced power Doppler sonography for diagnosing pancreatic carcinoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Restenosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Nocturnal IOP reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: CTF increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative pregnancy rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Average settling rates of lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of bacteremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Inulin kinetics in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distribution volume of inulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exchange parameter of inulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of type 2 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Change in immunohistologic scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients with clinically overt disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean histologic score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of bilirubin and liver enzymes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Active range of motion of proximal interphalangeal joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: perception of improved health care adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 24-hour hematoma growth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lower plasma phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: improved fatty acids status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from baseline in pain measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical objective response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of breast-conserving surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrease in alertness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in supine heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Increase in diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence and frequency of postoperative emesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discharge readiness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nasal IgA conversion factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Incidence of new edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pitting edema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient rated edema score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of BSS used
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of angina of Specific Activity Scale class II or worse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of exercise‐inducible ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life scores (SF-36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Fatal motorcycle crashes
Endpoint domain: Mortality/survival
Primary endpoint: Police-reported motorcycle crashes
Endpoint domain: Mortality/survival
Primary endpoint: Target-lesion failure at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean RAHO
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the experience of anaesthesia
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Patient-reported outcomes at two years after TKA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: fetal loss or perinatal death
Endpoint domain: Adverse events/effects
Primary endpoint: preterm prelabor rupture of membranes
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in functional capacity and mobility
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Preoperative perforating vein incompetence (PVI) reversal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: New vessel formation in venous junctions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reflux in the great saphenous vein (GSV) below the knee
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes